Nebulized treprostinil (Tyvaso) reduced lung function decline from idiopathic pulmonary fibrosis (IPF) in the pivotal TETON-1 ...

Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.

If you have chronic obstructive pulmonary disease (COPD)—an umbrella term for several lung diseases, including emphysema, ...

Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated ...

About 40% of at-risk patients with COPD did not receive maintenance therapy despite having frequent or severe exacerbations.

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new ...

Ralinepag, a prostacyclin receptor agonist, added to background therapy decreased the risk for a clinical worsening event in ...

What is Breztri?: A triple therapy inhaler combining three medications, prescribed for COPD patients not improving on double therapy. How it helps: Used twice daily, Breztri can reduce exacerbations ...

The GINA 2026 update covers primary care management of asthma exacerbations, fatality risk factors, biologic selection, and ...

Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically ...

Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary ...